1 year return (CAGR)
-34.02%
Summit Therapeutics PLC Exchange (NASDAQ, USD)
SMMT
15.77
-0.39 (-2.51%)
HealthcareBiotechnology
Loading...
3 year return (CAGR)
108.47%
5 year return (CAGR)
25.29%
10 year return (CAGR)
5.75%
Adobe 2026 Q3 – Is sentiment driving the price?
Read MoreMarketcap
12.07B
Price/Sales
-
Ent value
11.77B
Price/Book
-
Div yield
0.00%
Growth years
-
Div growth
-
FCF payout
0.00%
Trailing P/E
-
PEG
-
Forward P/E
-
EPS growth
-
Stock information
What is a stock exchange? Operation, actors, examples
Read MoreStock chart
Loading...
Stock price data
| Open | 15.26 |
| Daily high | 15.56 |
| Daily low | 15.04 |
| Daily Volume | 4.65M |
| All-time high | 36.70 |
| 1y analyst estimate | 29.77 |
| Beta | -1.24 |
| EPS (TTM) | -1.10 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 12 Mar 2026 |
Downside potential
Loading...
Downside potential data
| SMMT | S&P500 | |
| Current price drop from All-time high | -57.03% | -0.87% |
| Highest price drop | -95.75% | -56.47% |
| Date of highest drop | 1 Dec 2022 | 9 Mar 2009 |
| Avg drop from high | -57.82% | -10.65% |
| Avg time to new high | 126 days | 12 days |
| Max time to new high | 1758 days | 1805 days |
News
Summit Therapeutics secured a $2B strategic investment from AstraZeneca and enabling further clinical development of ivonescimab. Read more on SMMT stock here.
September 29, 2026
